escalating doses of recombinant human interleukin-2 ( ril-2 ) were combined with long-term cultured ril-2 activated killer cells to treat patients with disseminated melanoma , renal cell cancer , and colon cancer .
C0218986
ril-2
C0007134
renal cell cancer